Option chain shows key data for ImmuCell's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for ImmuCell.

ImmuCell (NASDAQ:ICCC) Stock, Option Chain

ImmuCell

ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.

PriceSmart

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

ICCC

KRUS

MANU

PSMT

PriceSmart, Kura Sushi And 3 Stocks To Watch Heading Into Wednesday

Penny Stocks

Small Cap

Movers

ADIL

ASTI

BANL

BDRX

CING

CRKN

CVKD

DTST

ELOX

ENOB

GDTC

HCTI

PIXY

PPBT

PRFX

SILK

VVOS

WLGS

Gainers


	Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) shares surged 131.6% to $4.03 in pre-market trading after gaining 15% on Tuesday.


Why ImmuCell Are Trading Higher; Here Are 20 Stocks Moving Premarket

ANGO

AZTR

MLKN

With U.S. stock futures trading slightly higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:

AngioDynamics, Disney And 3 Stocks To Watch Heading Into Wednesday

ImmuCell Corp

Press Releases

ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2024

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2024

ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2024

ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year 2024

General

ImmuCell Announces Settlement of Insurance Claim Related to Previously Disclosed Production Contamination Losses

ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2024

ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2024

ImmuCell Announces Initiation of Investigational Product Use of Re-Tain®

Management

ImmuCell Hires Chief Financial Officer

ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 of 2025

Adicet Bio

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

Alterity Therapeutics Limited - American Depositary Shares

Alterity Therapeutics

bluebird bio

BeyondSpring

Cabaletta Bio

Cibus

CytomX Therapeutics

Citius Oncology

Cue Biopharma

Precision BioSciences, Inc. - Common Stock

Precision BioSciences

Gain Therapeutics

Immix Biopharma

Immuneering Corporation - Class A Common Stock

Immuneering

Kronos Bio

MAIA Biotechnology

Metagenomi

PDS Biotechnology Corporation - Common Stock

PDS Biotechnology

PMV Pharma

Pyxis Oncology

Renovaro

Serina Therapeutics

Sutro Biopharma

vTv Therapeutics Inc. - Class A Common Stock

vTv Therapeutics

Comments

ImmuCell

ImmuCell (ICCC) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga